Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

Company Overview

Intellipharmaceutics International Inc. is a specialty pharmaceutical company focused on the development and commercialization of advanced oral drug delivery technologies. Headquartered in Ontario, Canada, the company’s core expertise lies in creating controlled-release and extended-release formulations designed to improve patient compliance by reducing dosing frequency and enhancing pharmacokinetic profiles.

The company’s proprietary L-ODDS™ (Long-Acting Oral Drug Delivery Systems) platform underpins its pipeline, enabling the development of dosage forms that deliver therapeutic agents over 24- to 72-hour periods. Intellipharmaceutics applies this platform to a range of molecules, including central nervous system agents and pain management therapies, with multiple candidates in preclinical and early clinical stages. The firm’s R&D efforts encompass formulation design, preclinical evaluation, manufacturing scale-up, and regulatory filing support.

In addition to in-house development, Intellipharmaceutics pursues strategic partnerships and licensing agreements with pharmaceutical firms to out-license its technology and co-develop product candidates. These collaborations aim to accelerate commercialization timelines and extend the reach of the L-ODDS platform into North American, European and Asian markets. By combining specialized formulation services with regulatory expertise, the company seeks to address unmet medical needs and deliver value to partners and patients alike.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 793,500 shs
• Average Volume: 12,042 shs
• Market Capitalization: $4.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPCIF Stock Analysis - Frequently Asked Questions

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) issued its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.70). The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.90 million.

When did Intellipharmaceutics International's stock split?

Intellipharmaceutics International's stock reverse split on Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/16/2018
• Today: 9/16/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IPCIF
• CIK: 1474835
• Web: www.intellipharmaceutics.com
• Phone: 416-798-3001
• Fax: 416-798-3007
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $660 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.32) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,093,000
• Free Float: 32,511,000
• Market Cap: $4.96 million
• Optionable: Not Optionable
• Beta: 1.53